Clinical Trial Update: A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the addition of bortezomib to GDP (gemcitabine, dexamethasone, cisplatin) chemotherapy in patients with refractory or relapsed non-GC…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Bortezomib (bortezomib)
• CISPLATIN (cisplatin)
• DEXAMETHASONE (Dexamethasone)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Ruijin Hospital | Conditions: Diffuse Large B-cell Lymphoma | Phase 2 | Status: UNKNOWN